Skip to main content
BC Innovations
Feature Story

Targets & Mechanisms: Joint attack

Targeting overactive fibroblasts could prevent joint damage in RA

By Stephen Parmley, Senior Writer

A newly discovered pathway that causes joint erosion in rheumatoid arthritis could lead to a new class of therapies that act locally in cells of the synovial lining and avoid the drawbacks of immunosuppressants.

The pathway was identified by a group at the La Jolla Institute for Allergy & Immunology, which found that activation of a receptor phosphatase on synovial fibroblasts reduced the cells' pathological activity.

Read Article

Today's Biotech & Pharma News

  • COVER STORY

    Joint attack

    Researchers have found a new pathway of joint destruction in RA that is based in synovial fibroblasts and could lead to therapies without the side effects of immunosuppressants.

  • PRODUCT R&D

    Altermune's Alphamers

    Altermune offers an alternative to classical antibiotics with its alphamers, which redirect existing antibodies to target pathogens.

  • A question of color

    Amgen and Lilly have upended the idea that FGF21 acts in obesity by causing fat browning, but the companies don't agree on what that means for the underlying biology.

  • TRANSLATION IN BRIEF

    c-Met's double-edged sword

    The effect of c-MET inhibitors on neutrophils could counteract their anti-tumor effect.

  • Mission to deplete

    Mission thinks its platform to find inhibitors of deubiquitinases can produce tractable compounds for cancer and other diseases.

  • Monitoring myelodysplasia

    Three studies uncover mechanisms behind the role of aberrant RNA splicing in myelodysplastic syndrome.

  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial